# A new and higher dose of obesity drug Wegovy has joined Novo Nordisk’s semaglutide portfolio, giving patients and doctors more options for treatment.

*biotech · news · 2026-05-21 · The Hindu Business Line*

## Key points

- Novo Nordisk is launching a higher 7.2 mg dose of Wegovy across Europe and the UK soon.
- Data shows early responders to high-dose Wegovy can achieve up to 28 percent weight loss.
- Novo Nordisk plans to seek regulatory approval for the higher dose Wegovy in India.
- Step-Up trial data found most high-dose Wegovy weight loss comes from fat, preserving lean mass.
- Semaglutide, both oral and injectable, has proven cardiovascular risk reduction benefits for postmenopausal women.

**Companies:** Novo Nordisk
**Countries:** India, Denmark, Turkiye, United Kingdom, Europe

[Read the full story on The Hindu Business Line](https://www.thehindubusinessline.com/companies/novo-nordisk-launches-higher-dose-wegovy-for-those-seeking-greater-weightloss/article71005775.ece)

---

Canonical: https://newsio.io/n/55223c9e-2bbb-43ee-899a-42cb988e4866/a-new-and-higher-dose-of-obesity-drug-wegovy-has-joined-novo-nordisks-semaglutid
Summarized by Newsio from The Hindu Business Line. https://newsio.io/how-it-works